Evaluating Disparities in Precision Oncology (EDPO)

Indiana University

Status: Enrolling

Conditions: Advanced Cancer; Metastatic Cancer

Treatments: Behavioral: Social Determinants of Health and toxicity questionnaires

Study type: Observational

Funder types: Other

Identifiers

NCT06081517

CTO-IUSCCC-0819

Details and patient eligibility

About

This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.

Full description

This study proposes an innovative approach leveraging the molecular tumor boards across four comprehensive cancer centers, where real- world, diverse patients with metastatic cancer are seen receiving a broad scope of therapies in the context of precision medicine. The study plans to collect detailed clinical, social, and genomic data from patients to identify significant contributors of disparate survival and toxicity outcomes for patients with metastatic cancer.

Enrollment: 10,600 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Ability to provide written informed consent and HIPAA authorization
2. Patients must be ≥ 18 years old at the time of consent
3. Patients planning to undergo molecular testing as part of their routine cancer care

Exclusion criteria

N/A

Trial design

10,600 participants in 2 patient groups

Black patients with advanced cancer

Treatment:

Behavioral: Social Determinants of Health and toxicity questionnaires

Non Black patients with advanced cancer

Treatment:

Behavioral: Social Determinants of Health and toxicity questionnaires